No data to show
OTCM
BVTXF
Market cap10mUSD
, Last price
USD
Name
BiVictriX Therapeutics PLC
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
1.90%
Rev. gr., 5y
%
Revenues
0k
Net income
-3m
L+1.92%
CFO
-2m
L-19.15%
Profile
BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia. The company was formerly known as BiVictriX Plc and changed its name to BiVictriX Therapeutics Plc in August 2021. BiVictriX Therapeutics Plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 2,047 | 2,999 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (2,047) | (2,999) | ||||
NOPBT Margin | ||||||
Operating Taxes | (458) | (474) | ||||
Tax Rate | ||||||
NOPAT | (1,589) | (2,525) | ||||
Net income | (2,545) 1.92% | (2,497) 6.76% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 2,133 | |||||
BB yield | ||||||
| Debt | ||||||
Debt current | 128 | 107 | ||||
Long-term debt | 268 | 483 | ||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | (2,883) | (2,697) | ||||
| Cash flow | ||||||
Cash from operating activities | (1,938) | (2,397) | ||||
CAPEX | (5) | (389) | ||||
Cash from investing activities | (5) | (379) | ||||
Cash from financing activities | 1,935 | |||||
FCF | (1,395) | (2,980) | ||||
| Balance | ||||||
Cash | 3,279 | 3,287 | ||||
Long term investments | ||||||
Excess cash | 3,279 | 3,287 | ||||
Stockholders' equity | (10,402) | (5,261) | ||||
Invested Capital | 14,410 | 9,473 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 72,645 | 66,115 | ||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | (1,882) | (2,848) | ||||
EV/EBITDA | ||||||
Interest | 4 | |||||
Interest/NOPBT | ||||||